CNJ.TO  Cangene Cp

Exchange

TSX

Sector

Life Sciences

Industry

Market Cap.

240.3M

Vuru Grade

39.25/100

Current Price

$3.60
0.00 (0.00%)

Growth Price

$4.10
Undervalued by 13.88%

Stability Price

$2.79
Overvalued by 22.48%

Company Metrics

  • 169 P/E
  • 2.08 P/S
  • 1.25 P/B
  • -0.15 EPS
  • 5.09% Cash ROIC
  • 1.68 Cash Ratio
  • 0 / 0% Dividend
  • 255,197.00 Avg. Vol.
  • 66.75M Shares
  • 240.3M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Canadians kept in dark about defective drugs
Toronto Star - Sep 11, 2014
At Cangene Corp. in Winnipeg, where the FDA also found side-effect information was not reported to the regulator, products that employees flagged as defective were nevertheless distributed to consumers.
Cangene Corp Announces FDA Approval Of Botulism Antitoxin
Reuters Key Development - Mar 25, 2013